Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

Our recent study demonstrated that a novel proteasome inhibitor NPI-0052 triggers apoptosis in multiple myeloma (MM) cells, and importantly, that is distinct from bortezomib (Velcade) in its chemical structure, effects on proteasome activities, and mechanisms of action. Here, we demonstrate that com...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Chauhan, Dharminder, Singh, Ajita, Brahmandam, Mohan, Podar, Klaus, Hideshima, Teru, Richardson, Paul, Munshi, Nikhil, Palladino, Michael A., Anderson, Kenneth C.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2008
Teme:
Neoplasia
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2214767/
https://ncbi.nlm.nih.gov/pubmed/18006697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-08-105601
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki